Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database (March 2019–March 2020), we analysed esketamine-related adverse events (AEs) to detect and characterize relevant safety signals. Methods: We used the consolidated case/non-case approach to estimate the reporting odds ratio (ROR) and information component (IC) with relevant confidence intervals (95% CI) for esketamine-related AEs with ≥4 counts. Comparisons between serious and non-serious AEs were performed using non-parametric tests. Results: The FAERS database contained 962 cases of esketamine-related AEs, with signals detected for several AEs, such as dissociation (ROR = 1,612.64, 95% CI = 1,354.63, 1,919.79; IC = 8.19, 95% CI = 7.96, 8.35), sedation (ROR = 238.46, 95% CI = 202.98, 280.15; IC = 7, 95% CI = 6.75, 7.18), feeling drunk (ROR = 96.17, 95% CI = 61.42, 150.57; IC = 4.84, 95% CI = 4.09, 5.36), suicidal ideation (ROR = 24.03, 95% CI = 18.72, 30.84; IC = 4.31, 95% CI = 3.9, 4.61), and completed suicide (ROR = 5.75, 95% CI = 3.18, 10.41; IC = 2.25, 95% CI = 1.23, 2.94). Signals for suicidal and self-injurious ideation, but not suicide attempt and completed suicide, remained when comparing esketamine to venlafaxine. Females and patients receiving antidepressant polypharmacy, co-medication with mood stabilizers, antipsychotics, benzodiazepines, or somatic medications were more likely to suffer from serious versus non-serious AEs (χ 2 = 125.29, p < 0.001, χ 2 = 9.08, p = 0.003, χ 2 = 8.14, p = 0.004, χ 2 = 19.48, p < 0.001, χ 2 = 25.62, p < 0.001, and χ 2 = 16.79, p < 0.001, respectively). Conclusions: Esketamine may carry a clear potential for serious AEs, which deserves urgent clarification by means of further prospective studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, a pharmacovigilance analysis found some specific patients reported more serious adverse events (women, obese people, people with comorbidities and with poly-pharmacy) [25].”
In the citing paper
“Possible safety issues have indeed been described in post-marketing studies [25, 52].”
In the citing paper
“As detailed above, esketamine-associated adverse events across trials have raised significant concern, particularly with regard to inducing suicidality [115].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [115]
Citations
Cites
Evans, S. J. W., Waller, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,802
A Bayesian neural network method for adverse drug reaction signal generation
Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., & De Freitas, R. M. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050466 · Cited by 1,476
Ford, I., & Norrie, J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510059 · Cited by 1,405
van Puijenbroek, E. P., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R., & Egberts, A. C. G. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.668 · Cited by 1,372
Explanatory and Pragmatic Attitudes in Therapeutical Trials
Schwartz, D., & Lellouch, J. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.01.012 · Cited by 1,252
Explanatory and pragmatic attitudes in therapeutical trials
Schwartz, D., & Lellouch, J. (1967) · Journal of Chronic Diseases · doi:10.1016/0021-9681(67)90041-0 · Cited by 1,185
The reporting odds ratio and its advantages over the proportional reporting ratio
Rothman, K. J., Lanes, S., & Sacks, S. T. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1001 · Cited by 1,111
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6048 · Cited by 1,048
Quantitative signal detection using spontaneous ADR reporting
Bate, A., & Evans, S. J. W. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1742 · Cited by 912
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Ceban, F., Rosenblat, J. D., Kratiuk, K., Lee, Y. L., Rodrigues, N. B., Gill, H., Subramaniapillai, M., Nasri, F., Lui, L. M. W., Lipsitz, O., et al. (2021) · CNS Drugs · doi:10.1007/s40263-021-00846-5 · Cited by 102
Kantrowitz, J. T., Dong, Z., Milak, M. S., Rashid, R., Kegeles, L. S., Javitt, D. C., Lieberman, J. A., & John Mann, J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01541-1 · Cited by 100
“Better understanding of glutamatergic and GABA pathophysiology in depression may aid identification of new effective antidepressant medications, that can act rapidly like ketamine, but can be used orally and have fewer side effects and less abuse potential than ketamine [15, 16].”
BackgroundEsketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Shu, Y., Ding, Y., He, X., Liu, Y., Wu, P., & Zhang, Q. (2022) · Cancer Medicine · doi:10.1002/cam4.5062 · Cited by 86
Gastaldon, C., Schoretsanitis, G., Arzenton, E., Raschi, E., Papola, D., Ostuzzi, G., Moretti, U., Seifritz, E., Kane, J. M., Trifirò, G., et al. (2022) · Drug Safety · doi:10.1007/s40264-022-01246-4 · Cited by 64
“Specifically, the attention recently received by these antidepressants may have inflated the number of reports and the RORs, as also found by a recent work by Chiappini et al [13, 20].”
BackgroundResultSelf-citationThe correlation of Esketamine with specific adverse events: a deep dive into the FAERS database
Jiang, Y., Du, Z., Shen, Y., Zhou, Q., & Zhu, H. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01732-5 · Cited by 74
“In the literature analyzing the adverse reactions reported to the FDA within 1 year of Esketa-mine’s market release (from March 2019 to March 2020) [22], 962 patients reported 2274 adverse reactions associated with Esketamine use.”
Rapid-acting antidepressants and the circadian clock
Sato, S., Bunney, B. G., Mendoza-Viveros, L., Bunney, W. E., Borrelli, E., Sassone‐Corsi, P., & Orozco-Solís, R. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01241-w · Cited by 72
“Ketamine has two enantiomers, (S) and (R); intranasal esketamine (S-ketamine) has been recently approved by the FDA [74].”
BackgroundSapkota, A., Khurshid, H., Qureshi, I. A., Jahan, N., Went, T. R., Sultan, W., & Alfonso, M. (2021) · Cureus · doi:10.7759/cureus.17352 · Cited by 63
“In addition to the above mentioned AE, a case/non-case study [13] detected some rare AEs, which have not been reported by most studies.”
BackgroundMethodResultReporting of harms in clinical trials of esketamine in depression: a systematic review
de Laportalière, T. T., Jullien, A., Yrondi, A., Cestac, P., & Montastruc, F. (2023) · Psychological Medicine · doi:10.1017/s0033291723001058 · Cited by 58
“Finally, these discrepancies results confirm that post-marketing studies of AEs in real life are needed (Gastaldon et al., 2021).”
BackgroundResultKetamine and esketamine in suicidal thoughts and behaviors: a systematic review
Jollant, F., Colle, R., Nguyen, T. M. L., Corruble, E., Gardier, A. M., Walter, M., Abbar, M., & Wagner, G. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231151327 · Cited by 56
Woods, R. H. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15581 · Cited by 52
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“As detailed above, esketamine-associated adverse events across trials have raised significant concern, particularly with regard to inducing suicidality [115].”
BackgroundResearch advances in the clinical application of esketamine
Zhang, X., Zhang, N., Liu, D., Ding, J., Zhang, Y., & Zhu, Z. (2022) · Ibrain · doi:10.1002/ibra.12019 · Cited by 47
“The incidence of such adverse reactions is greater in women than in men.(102,103) When used as an analgesic and sedative drug, the incidence of side effects of esketamine is lower than that of ketamine, the reaction is mild and tolerable, and there is no gender difference.”
Langmia, I. M., Just, K. S., Yamoune, S., Müller, J. P., & Stingl, J. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15467 · Cited by 47
Fusaroli, M., Raschi, E., Giunchi, V., Menchetti, M., Rimondini, R., Ponti, F. D., & Poluzzi, E. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac031 · Cited by 44
Self-citationEntheogens and psychedelics in Canada: Proposal for a new paradigm.
Rochester, J., Vallely, A., Grof, P., Williams, M. T., Chang, H., & Caldwell, K. (2022) · Canadian Psychology/Psychologie canadienne · doi:10.1037/cap0000285 · Cited by 42
Xing, X., Zhang, X., Wang, K., Wang, Z., Feng, Y., Li, X., Hua, Y., Zhang, L., & Dong, X. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01669-4 · Cited by 42
“…least 5% of participants; (b) Expected AEs without a signal: Predictable events based on the above criteria but without a signal; (c) Disease-related AEs: Events associated with the Alzheimer’s disease being treated; (d) Unex-pected AEs: Events that were unexpected or not previously reported [19].”
InfluentialWilkowska, A., Włodarczyk, A., Gałuszko‐Węgielnik, M., Wiglusz, M. S., & Cubała, W. J. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s325000 · Cited by 41
Guo, H., Wang, B., Yuan, S., Wu, S., Liu, J., He, M., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.849758 · Cited by 38
“This real-world study detected a range of new, unexpected signals and identified several risk factors related to AEs severity, such as the female, patients treated with higher doses, and those receiving multidrug therapy (Gastaldon et al., 2020).”
BackgroundResultInfluentialHu, J.-H., Zhong, Z.-Z., Shi, H.-J., Wang, J., Chen, S., Shan, X.-S., Liu, H., Liu, H., Meng, L., Ji, F., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002060 · Cited by 29
Gastaldon, C., Arzenton, E., Raschi, E., Spigset, O., Papola, D., Ostuzzi, G., Moretti, U., Trifirò, G., Barbui, C., & Schoretsanitis, G. (2022) · Psychological Medicine · doi:10.1017/s0033291722002859 · Cited by 27
Self-citationBaudot, J., Soeiro, T., Tambon, M., Navarro, N., Veyrac, G., Mezaache, S., & Micallef, J. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12745 · Cited by 26
“The first disproportionality analysis for esketamine was conducted using FAERS, and shows that esketamine carry a clear potential for serious adverse events, such as dissociation, sedation, and feeling drunk [11].”
MethodZhuang, W., Lu, M., Wu, Y., Chen, Z., Wang, M., Wang, X., Guan, S., & Lin, W. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01320-4 · Cited by 24
“These systems serve as an invaluable resource for early detection and identification of potential adverse effects and allow for continuous monitoring and tracking of AEs over time after data mining [16, 17].”
BackgroundYang, J.-R., Li, Y.-Y., Ran, T., Lin, X., Xu, J.-Y., Zhou, S., & Huang, P. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s460924 · Cited by 24
“38,39 According to our observations, these reactions can spontaneously resolve within 10–20 minutes after drug infusion.”
BackgroundNicola, M. D., Pepe, M., d’Andrea, G., Marcelli, I., Pettorruso, M., Andriola, I., Barlati, S., Carminati, M., Cattaneo, C. I., Clerici, M., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15040161 · Cited by 24
Ren, L. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110910 · Cited by 23
“In the clinic, the application of ketamine is hampered by the risk of misuse and the potential development of adverse effects, including neurotoxicity and dissociative reactions (Vieira et al., 2021; Yang et al., 2022; Gastaldon et al., 2021; Short et al., 2018; Kasper et al., 2021).”
BackgroundFusaroli, M., Pelletti, G., Giunchi, V., Pugliese, C., Bartolucci, M., Necibi, E. N., Raschi, E., Ponti, F. D., Pelotti, S., & Poluzzi, E. (2023) · Drug Safety · doi:10.1007/s40264-022-01269-x · Cited by 24
Self-citationBayes, A. J., Short, B., Zarate, C. A., Park, L., Murrough, J. W., McLoughlin, D. M., Riva‐Posse, P., Schoevers, R. A., Veraart, J. K. E., Parikh, S. V., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.020 · Cited by 22
“Post-marketing intranasal esketamine data has led to some discussion of whether further clarification of safety is required in the domains of dissociation, sedation and suicidal ideation (Gastaldon et al., 2021; Doherty et al., 2021).”
Li, H., Zhang, M., Jiao, X., Zhu, Y., Liu, Y., Zeng, L., Wang, H., Zhang, L., Zhang, W., & Zhang, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-27687-0 · Cited by 22
Levin, A. W., Nagib, P. B., Deiparine, S., Gao, T. Z., Mitchell, J. J., & Davis, A. K. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103816 · Cited by 23
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenytė, A., Strumila, R., Olié, É., & Courtet, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.004 · Cited by 21
Ren, L., Zhang, H., Tao, W., Chen, Y., Zou, Z., Guo, X., Shen, Q., Feng, Q., & Hu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.896628 · Cited by 21
Xiao, Y., Chen, Y., Huang, Y., & Yuan, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-37944-x · Cited by 20
Gui, X., Zhao, J., Ding, L., Chai, J., Lai, H., Cai, Y., Luo, S., Zeng, Y., Wu, W., Chen, H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1276976 · Cited by 20
Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality
Mathai, D. S., McCathern, A. G., Guzick, A. G., Schneider, S. C., Weinzimmer, S. A., Cepeda, S. L., Garcia‐Romeu, A., & Storch, E. A. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2021.0078 · Cited by 19
Is there a risk of esketamine misuse in clinical practice?
Roncero, C., Torres, M. M., Szerman, N., Torrens, M., Vega, P., Andrés-Olivera, P., & Alvarez, E. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241310685 · Cited by 18
Harding, F., Seynaeve, M., Keeler, J. L., Himmerich, H., Treasure, J. L., & Kan, C. (2021) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2003059 · Cited by 18
New Adverse Drug Reaction Signals from 2017 to 2021—Genuine Alerts or False Alarms?
Loke, Y. K., Mattishent, K., & Navaneetharaja, N. (2024) · Pharmacy · doi:10.3390/pharmacy12010033 · Cited by 18
Guo, H., Tang, L., He, M., Tang, W., Liu, J., Wu, S., Yuan, S., Wang, J., & Tang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1681060 · Cited by 16
McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., Teopiz, K. M., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2368827 · Cited by 16
“Our results represent an update of a previous analysis of ketamine/esketamine in association with suicidality using the FAERS database [25,26].”
Comparing the adverse effects of ketamine and esketamine between genders using FAERS data
Yang, X., & Chen, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1329436 · Cited by 16
Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression
Price, M. Z., & Price, R. L. (2024) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2024.100104 · Cited by 16
Mapping consent practices for outpatient psychiatric use of ketamine
Mathai, D. S., Lee, S. M., Mora, V., O’Donnell, K. C., Garcia‐Romeu, A., & Storch, E. A. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.036 · Cited by 16
“IC-Docs inconsistently addressed the growing concerns around treatment-emergent suicidality (Gastaldon et al., 2021).”
BackgroundZhang, M., Xie, W., Li, J., Zheng, J., & Zhou, Y. (2023) · Archives of Women s Mental Health · doi:10.1007/s00737-023-01378-1 · Cited by 16
Lin, W., Xu, J., Liao, Y., Lin, X., Yang, J., & Zhuang, W. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01673-y · Cited by 15
Ren, L., Zhang, H., Tao, W., Xue, W., Yin, C., Zou, Z., Guo, X., Shen, Q., Wang, W., Jiang, H., et al. (2023) · Neuropeptides · doi:10.1016/j.npep.2023.102350 · Cited by 14
“However, evidence from clinical trials demonstrated the serious adverse effects, and other disadvantages such as stringent restrictions on medical indications also limited the clinical application of Spravato (Gastaldon et al., 2021; Kasper et al., 2021; Vieira et al., 2021; Yang et al., 2022).”
BackgroundGarel, N., Greenway, K. T., Dinh-Williams, L.-A. L., Thibault-Levesque, J., Jutras-Aswad, D., Turecki, G., Rej, S., & Richard-Devantoy, S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01689-y · Cited by 13
“Our ketamine-TRD service routinely attempts to discontinue all BZDRs given preliminary (albeit conflicting [23]) evidence that they may blunt ketamine’s antidepressant effects [22] and increase the rate of serious adverse events (according to post-marketing study of esketamine) [24], in addition to the potential long-…”
BackgroundZhao, D., Zhang, W., Liu, Y., & Yan, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1389814 · Cited by 13
Zhang, Z.-N., Hao, X.-Y., Cai, C., Sun, L., Zhang, Z., Wang, M., Wu, Y., Wang, Y., Cao, J., Liu, Y., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108047 · Cited by 16
Li, Y., Wang, X., Liao, Y., Zeng, Y., Lin, W., & Zhuang, W. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09339-4 · Cited by 13
“These systems, particularly the FDA Adverse Event Reporting System (FAERS), serve as valuable resources for early detection and identification of potential adverse effects, facilitating continuous monitoring and tracking of AEs over time through data mining [6, 7].”
BackgroundPorwal, M. H., Razzak, A. N., Kumar, V., Obeidat, A. Z., & Sharma, U. (2024) · Epilepsy Research · doi:10.1016/j.eplepsyres.2024.107382 · Cited by 13
How to deprescribe esketamine in resistant depression? A point of view after first clinical uses
de Laportalière, T. T., Yrondi, A., Jullien, A., Cestac, P., & Montastruc, F. (2022) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602100072x · Cited by 13
Dong, Z., Grunebaum, M. F., Lan, M. J., Wagner, V., Choo, T.-H. J., Milak, M. S., Sobeih, T. M., Mann, J. J., & Kantrowitz, J. T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.653026 · Cited by 13
Qiu, L., Chen, X., Fu, J., Chen, X., & Wang, X. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06035-0 · Cited by 13
Włodarczyk, A., Dywel, A., & Cubała, W. J. (2023) · Pharmaceuticals · doi:10.3390/ph16020173 · Cited by 12
“Although it must be noted that real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System database detected new, unexpected signals, with serious adverse events, clearly indicating that further studies on ketamine/esketamine are needed [18,19].”
BackgroundFragile promise of psychedelics in psychiatry
Lemarchand, C., Chopin, R., Paul, M., Braillon, A., Cosgrove, L., Cristea, I., Fried, E. I., Turner, E. H., & Naudet, F. (2024) · BMJ · doi:10.1136/bmj-2024-080391 · Cited by 11
Esketamine: uncertain safety and efficacy data in depression
Horowitz, M. A., & Moncrieff, J. (2021) · The British Journal of Psychiatry · doi:10.1192/bjp.2021.163 · Cited by 11
Zhuang, W., Xu, J., Wu, Y., Yang, J., Lin, X., Liao, Y., Wan, J., Weng, L., & Lin, W. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15783 · Cited by 11
Drug-induced psychiatric disorders: A pharmacovigilance update
Montastruc, F., & de Laportalière, T. T. (2023) · Therapies · doi:10.1016/j.therap.2023.09.007 · Cited by 11
Niu, X., Zheng, Y., Wang, W., Zhang, L., Wang, S., Lu, X., Wang, J., Yang, G., Zhao, T. C., Li, Q., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70145 · Cited by 10
Liu, T., Wu, J., Huang, P., Cheng, W.-L., & Lai, C. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.07.006 · Cited by 10
A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab
Chen, Z., Li, M., Li, S., Li, Y., Wu, J., Qiu, K., Yu, X., Huang, L. C., & Chen, G. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2130891 · Cited by 9
“Their results indicated that some of esketamine AEs might resemble effects of recreational drugs, including the signal for increased reporting of suicidal ideation [14].”
Backgroundde Filippis, R., Fazio, P. D., Kane, J. M., & Schoretsanitis, G. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2066078 · Cited by 9
“Moreover, pharmacovigilance databases provide an important platform for post-marketing surveillance, particularly for newly licensed medications with limited clinical experience [2].”
BackgroundSelf-citationBloomfield-Clagett, B., Ballard, E. D., Greenstein, D. K., Wilkinson, S. T., Grunebaum, M. F., Murrough, J. W., Mathew, S. J., Phillips, J. L., Fava, M., Sanacora, G., et al. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac055 · Cited by 8
Ammendolia, I., Mannucci, C., Esposito, E., Calapai, G., Currò, M., Midiri, P., Mondello, C., Cardia, L., & Calapai, F. (2025) · Pharmaceuticals · doi:10.3390/ph18050702 · Cited by 8
“The authors of the study concluded that esketamine may carry a clear potential for serious adverse events, which requires urgent clarification [45].”
de Filippis, R., & Fazio, P. D. (2023) · Bipolar Disorders · doi:10.1111/bdi.13375 · Cited by 8
Ma, B., Tao, X., Qi, Y., Cao, H., Cao, Q., Zhou, Z., & Wang, S. (2024) · Medicine · doi:10.1097/md.0000000000038821 · Cited by 8
“[25,26] These concerns suggest that esketamine is a double-edged sword, capable of being antidepressant by acting on NMDAR and also producing corresponding psychiatric symptomatic side effects via NMDAR.”
BackgroundWeleff, J., Bryant, K. A., Kovacevich, A., & Barnett, B. S. (2022) · Case Reports in Psychiatry · doi:10.1155/2022/1104668 · Cited by 8
“75 increased odds for completed suicide attempt compared to other medications [12].”
BackgroundYang, Z., Wang, C., Wei, S., Liu, Y., He, M., Zheng, C., Li, W., Li, D., & Liu, P. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2568971 · Cited by 7
“…regarding potential drug-event associations by comparing the reporting rates of specific aEs for a single drug or pharmacological class with the reporting rates of the same aEs in a reference group, this method is currently one of the more established techniques for detecting aE signals [6,7].”
Black, J. C., Monte, A. A., Dasgupta, N., Jewell, J. S., Rockhill, K. M., Olson, R. A., & Dart, R. C. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00233-1 · Cited by 7
“Postmarketing surveillance systems struggle to distinguish between these events as emergent from treatment versus emergent from the underlying disease 24 .”
Liu, L., Hu, J.-H., Pan, J., Liu, H., Ji, F., & Peng, K. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s421265 · Cited by 7
“The administration of esketamine may cause several side effects, such as headache, nausea and vomiting, excessive salivation, dissociation, and elevated blood pressure and heart rate, which are often dose-dependent and transient.(33,34) In our study, we use a sub-anesthetic dose of esketamine (0.”
MethodLiu, R., Liu, C., Feng, D., Guo, T., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1414703 · Cited by 7
Completed suicides and intranasal esketamine therapy: A case report and case series
Rayburn, W. F., & Albright, B. B. (2023) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2023.100104 · Cited by 7
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg
McIntyre, R. S. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21060653r · Cited by 7
Naudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A. (2025) · BMC Medicine · doi:10.1186/s12916-025-04435-x · Cited by 6
Self-citationPACAP/VIP in the prefrontal cortex mediates the rapid antidepressant effects of zhizichi decoction
Ren, L., Fan, Y., Luo, H., Hu, J., & Hu, J. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118638 · Cited by 6
A real-world pharmacovigilance study of esketamine nasal spray
Chen, Y., Gu, H., Li, W., & Chen, Y. (2024) · Medicine · doi:10.1097/md.0000000000039484 · Cited by 6
“…of the Risk Evaluation and Mitigation Strategy (REMS) program by the FDA on 3rd May 2019, could have contributed to an increase in the number of reports on esketamine nasal spray, [12] which illustrating at its post-launch safety message is still one that is important to be taken into account.”
Yu, X., Xu, X., Wang, J., Wang, Z., & Zhang, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s519732 · Cited by 6
“Gastaldon 17 found that the FAERS database contains 962 cases of esketamine-related adverse reactions, among which 18 were esketamine-related neurological adverse reactions.”
Chen, H., & Li, Y. (2026) · Headache The Journal of Head and Face Pain · doi:10.1111/head.70049 · Cited by 6
Tamman, A. J. F., Anand, A., & Mathew, S. J. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2049754 · Cited by 7
“side effects in clinical trials compared to real-life, in particular in patients with higher BMI, female, or those receiving 84 mg of esketamine compared to 56 mg [169].”
BackgroundLi, J., Ma, L., Sun, H., Li, M., Cao, Y., Peng, Y., & Xu, J. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01920-x · Cited by 5
Liu, Y., Zhang, Z., Zhao, Y., Jiang, R., Geng, Z., Tao, Y., Zhang, J., & Tao, W. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119628 · Cited by 5
Donati, M., Boccia, A., Ponti, F. D., Poluzzi, E., & Raschi, E. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01699-6 · Cited by 5
Self-citationUncovering safety signals of duloxetine: Real-world evidence from the FAERS database
Liu, D., Li, N., Liu, L., Qiu, L., Zhou, Z., & Wu, J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119517 · Cited by 5
Pisanu, C., Imai, S., Tsuchiya, M., Inoue, M., Ikegami, K., Zammarchi, G., Kizaki, H., & Hori, S. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03954-z · Cited by 5
Comments to Drs. Gastaldon, Raschi, Kane, Barbui, and Schoretsanitis
Doherty, T., Daly, E., Miller, J., Popova, V., Cepeda, M. S., Drevets, W. C., & Canuso, C. M. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000512311 · Cited by 5
Zhang, X., Liu, Y., Xie, W.-X., Mao, Y., Liu, A., Huang, S., Hong, W.-P., Hong, Y.-F., Xu, X., & Chen, Z.-Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115860 · Cited by 4
Fremont, R., Karim, A., Estevez, T. P., McDonough, C., LaBarbiera, A., Feder, A., Naasan, G., Delgado, A. D., Ds, C., & Murrough, J. W. (2026) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2026.02.005 · Cited by 4
An, J., Li, X., Li, Z., Wang, J., & Pan, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04417-y · Cited by 5
de la Barquera, J. A. O.-S., García, L. A. D. L. G., García, S. V. E., Torres, G. S., & Jalomo, G. A. P. (2024) · American Journal of Case Reports · doi:10.12659/ajcr.945475 · Cited by 4
“Gastaldon et al analyzed the safety concerns of esketamine and suicidal risk [13].”
Deng, B., Fu, Z., Li, L., Xu, Y., Yang, Z., Zhai, X., & Lv, Y. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00992-2 · Cited by 4
Psychedelics for treating psychiatric disorders: Are they safe?
Thakur, M. (2022) · Current Psychiatry · doi:10.12788/cp.0309 · Cited by 4
Considering New and Emerging Treatment Strategies for Depression: Beyond STAR*D and the Monoamines
McInnes, L. A., & Marton, T. F. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822284575240130053259 · Cited by 4
Luo, H., Yang, Y., He, Z., Pan, C., Wu, X., Cao, S., & Zhang, J. (2025) · Journal of Pain Research · doi:10.2147/jpr.s533143 · Cited by 3
“10 Xu et al found that intravenous administration of esketamine can lead to neuropsychiatric adverse reactions, such as hallucinations, vivid dreams, and dizziness.”
Li, C., Wang, Z., Ye, X., Lv, J., Chen, F., Zhang, Y., Liu, J., Li, X., Duan, J., Wang, Y., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1692751 · Cited by 3
Chan, L. F., Woon, L. S., Shukor, N. A. M., Eu, C. L., Ismail, N., Chin, S. J., Jaafar, N. R. N., & Baharudin, A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.890099 · Cited by 3
Taillefer de Laportalière, T., Horowitz, M. A., Soeiro, T., Lepetit, M., Jullien, A., Yrondi, A., Moncrieff, J., Naudet, F., & Montastruc, F. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.03.009 · Cited by 2
Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations
Marazziti, D., Gambini, M., Gurrieri, R., Russomanno, G., Sità, G., Pescini, E., DIGIUSEPPE, F. R., & Mucci, F. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2654682 · Cited by 2
Safety evaluation of Tofersen in amyotrophic lateral sclerosis based on the FAERS database
Xiao, X., Hao, G., Wan, P., & Hou, W. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1843630 · Cited by 2
“Studies suggest that signal strength in dispropor-tionality analyses of marketed drugs is broadly consistent with relative risk estimates and may serve as a rough indicator of clinical relevance (27).”
Metadata
- Authors
- Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G.
- Affiliations
- University of Verona (IT)
- University of Bologna (IT)
- Northwell Health (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2020-08-27
- Volume
- 90
- Issue
- 1
- Pages
- 41-48
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W3082360571
- Cited by
- 134
- References
- 54
- Citations by year
- 2026: 18 · 2025: 26 · 2024: 25 · 2023: 22 · 2022: 25 · 2021: 16 · 2020: 2
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- esketamine, treatment-resistant depression, post-marketing safety, adverse event signals, dissociation, sedation, suicidal ideation, suicide mortality, venlafaxine, mood stabilizers, FDA Adverse Event Reporting System, reporting odds ratio, information component, serious adverse events, sex differences in adverse events
- MeSH terms
- Female, Humans, Ketamine, Prospective Studies, Adverse Drug Reaction Reporting Systems, Marketing, Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.